INOVIQ Receives Australian patent for SubB2M technology
- INOVIQ (IIQ) receives an Australian patent for its SubB2M technology, which the company now holds exclusive worldwide rights to the IP for its diagnostic applications
- The company was awarded the Australian Patent number 2017358401 entitled “Subtilase cytotoxin B subunit mutant”, issued to Griffith University and the University of Adelaide
- The patent is due to expire on November 9, 2037
- The granting of the Australian patent is another important step in the company’s path to commercialisation for its SubB2M-based tests and follows other recent key milestones
- IIQ shares are up 6.14 per cent, trading at 60.5 cents
